At the close of 2015, there were 41 biosimilars under development for four key biologics going off patent, a new report from the IMS Institute for Health Informatics points out.
It’s clear that more biosimilars are close to completion and marketing than not; 12 are in preclinical development, whereas 23 are almost ready to be filed.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Some manufacturers have already filed marketing authorizations for three of these drugs: Amgen’s ABP501 was filed last year as a biosimilar candidate for Humira (adalimumab), and Aprogen filed two drugs – G5071, which mimics Remicade (infliximab) and AP052, which mimics Rituxan (rituximab).
Many more are in late stage development, and should make it to market in time for these drugs to go off-patent.
